Palivizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus Infection
Conditions
Respiratory Syncytial Virus Infection
Trial Timeline
Aug 1, 2011 → Apr 1, 2012
NCT ID
NCT01466062About Palivizumab
Palivizumab is a phase 3 stage product being developed by AbbVie for Respiratory Syncytial Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01466062. Target conditions include Respiratory Syncytial Virus Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02968173 | Phase 3 | Completed |
| NCT01466062 | Phase 3 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus Infection